milrinone has been researched along with Chronic Illness in 20 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Milrinone, a phosphodiesterase inhibitor, enhances cardiac contractility by increasing intracellular levels of cyclic AMP, but the long-term effect of this type of positive inotropic agent on the survival of patients with chronic heart failure has not been determined." | 9.07 | Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. ( Bommer, WJ; Carver, JR; DiBianco, R; Elkayam, U; Hendrix, GH; Ivanhoe, RJ; Kukin, ML; Packer, M; Rodeheffer, RJ; Zeldis, SM, 1991) |
| "The response of patients with chronic severe heart failure to extended infusions (greater than or equal to 48 hours) of milrinone was evaluated in a multicenter, baseline-controlled, phase III efficacy and safety trial in 189 patients in the United States." | 9.07 | Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. ( Anderson, JL, 1991) |
| "We randomly assigned 230 patients in sinus rhythm with moderately severe heart failure to treatment with digoxin, milrinone, both, or placebo." | 9.06 | A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. ( DiBianco, R; Kostuk, W; Moran, J; Schlant, RC; Shabetai, R; Wright, R, 1989) |
| "Thirty-seven patients with severe chronic heart failure were entered into an open-ended trial with milrinone at an initial daily dose ranging form 20 to 30 mg." | 9.06 | Milrinone for long-term therapy of severe heart failure: clinical experience with special reference to maximal exercise tolerance. ( Chadwick, B; Gumbardo, D; LeJemtel, TH; Rutman, HI; Sonnenblick, EH, 1986) |
| "This investigation demonstrates the well-known hemodynamic and inotropic effects of milrinone which, in the setting of monocrotaline pyrrole-induced pulmonary hypertension, were also associated with significant increases in pulmonary blood flow and left ventricular filling." | 7.69 | Milrinone improves pulmonary hemodynamics and right ventricular function in chronic pulmonary hypertension. ( Bittner, HB; Chen, EP; Davis, RD; Van Trigt, P, 1997) |
| "To determine the magnitude and time course of the optimal acute hemodynamic response to oral milrinone, an ascending dose range study was performed in 34 patients with severe chronic congestive heart failure (2." | 7.67 | Acute dose range study of milrinone in congestive heart failure. ( Chatterjee, K; Cody, RJ; Kubo, SH; Leonard, D; Rutman, H; Simonton, C, 1985) |
| " Our aim was to compare acute dose-response hemodynamic effects of inodilators dobutamine (DOB), milrinone (MIL), and levosimendan (LEV) in chronic experimental PH." | 5.46 | Dose-Response Head-to-Head Comparison of Inodilators Dobutamine, Milrinone, and Levosimendan in Chronic Experimental Pulmonary Hypertension. ( Alaa, M; Leite, S; Leite-Moreira, AF; Lopes, L; Lourenço, AP; Oliveira-Pinto, J; Tavares-Silva, M, 2017) |
| "Milrinone levels were 216±71 ng/ml (within the reported therapeutic range: 100-300 ng/ml), followed by improvements in cardiac index, pulmonary artery and wedge pressures (p < 0." | 5.40 | Milrinone in advanced heart failure: dose and therapeutic monitor outside intensive care unit. ( Banner, NR; Charisopoulou, D; Leaver, N, 2014) |
| "Milrinone, a phosphodiesterase inhibitor, enhances cardiac contractility by increasing intracellular levels of cyclic AMP, but the long-term effect of this type of positive inotropic agent on the survival of patients with chronic heart failure has not been determined." | 5.07 | Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. ( Bommer, WJ; Carver, JR; DiBianco, R; Elkayam, U; Hendrix, GH; Ivanhoe, RJ; Kukin, ML; Packer, M; Rodeheffer, RJ; Zeldis, SM, 1991) |
| "The response of patients with chronic severe heart failure to extended infusions (greater than or equal to 48 hours) of milrinone was evaluated in a multicenter, baseline-controlled, phase III efficacy and safety trial in 189 patients in the United States." | 5.07 | Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. ( Anderson, JL, 1991) |
| "We randomly assigned 230 patients in sinus rhythm with moderately severe heart failure to treatment with digoxin, milrinone, both, or placebo." | 5.06 | A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. ( DiBianco, R; Kostuk, W; Moran, J; Schlant, RC; Shabetai, R; Wright, R, 1989) |
| "Thirty-seven patients with severe chronic heart failure were entered into an open-ended trial with milrinone at an initial daily dose ranging form 20 to 30 mg." | 5.06 | Milrinone for long-term therapy of severe heart failure: clinical experience with special reference to maximal exercise tolerance. ( Chadwick, B; Gumbardo, D; LeJemtel, TH; Rutman, HI; Sonnenblick, EH, 1986) |
| "Patients who experience severe symptoms of heart failure and repeated hospitalizations for exacerbations may benefit from positive inotropic drug infusion therapy such as dobutamine or milrinone." | 3.71 | Positive inotropic drug infusions for patients with heart failure: current controversies and best practice. ( Gorski, LA, 2002) |
| "This investigation demonstrates the well-known hemodynamic and inotropic effects of milrinone which, in the setting of monocrotaline pyrrole-induced pulmonary hypertension, were also associated with significant increases in pulmonary blood flow and left ventricular filling." | 3.69 | Milrinone improves pulmonary hemodynamics and right ventricular function in chronic pulmonary hypertension. ( Bittner, HB; Chen, EP; Davis, RD; Van Trigt, P, 1997) |
| "To determine the magnitude and time course of the optimal acute hemodynamic response to oral milrinone, an ascending dose range study was performed in 34 patients with severe chronic congestive heart failure (2." | 3.67 | Acute dose range study of milrinone in congestive heart failure. ( Chatterjee, K; Cody, RJ; Kubo, SH; Leonard, D; Rutman, H; Simonton, C, 1985) |
| "Milrinone was administered intravenously in successive doses of 25, 50, and 75 micrograms/kg." | 2.66 | Milrinone in the treatment of chronic cardiac failure: a controlled trial. ( Andrews, V; Janicki, JS; Likoff, MJ; Rocci, ML; Weber, KT; Wilson, H, 1985) |
| " Our aim was to compare acute dose-response hemodynamic effects of inodilators dobutamine (DOB), milrinone (MIL), and levosimendan (LEV) in chronic experimental PH." | 1.46 | Dose-Response Head-to-Head Comparison of Inodilators Dobutamine, Milrinone, and Levosimendan in Chronic Experimental Pulmonary Hypertension. ( Alaa, M; Leite, S; Leite-Moreira, AF; Lopes, L; Lourenço, AP; Oliveira-Pinto, J; Tavares-Silva, M, 2017) |
| "Milrinone levels were 216±71 ng/ml (within the reported therapeutic range: 100-300 ng/ml), followed by improvements in cardiac index, pulmonary artery and wedge pressures (p < 0." | 1.40 | Milrinone in advanced heart failure: dose and therapeutic monitor outside intensive care unit. ( Banner, NR; Charisopoulou, D; Leaver, N, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (40.00) | 18.7374 |
| 1990's | 7 (35.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 2 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tavares-Silva, M | 1 |
| Alaa, M | 1 |
| Leite, S | 1 |
| Oliveira-Pinto, J | 1 |
| Lopes, L | 1 |
| Leite-Moreira, AF | 1 |
| Lourenço, AP | 1 |
| Charisopoulou, D | 1 |
| Leaver, N | 1 |
| Banner, NR | 1 |
| Gheorghiade, M | 1 |
| Gattis, WA | 1 |
| Klein, L | 1 |
| Watanabe, H | 1 |
| Kajimoto, K | 1 |
| Kawana, M | 1 |
| Chen, EP | 2 |
| Bittner, HB | 2 |
| Davis, RD | 2 |
| Van Trigt, P | 2 |
| Craig, DM | 1 |
| Gorski, LA | 1 |
| Desjardins, S | 1 |
| Packer, M | 1 |
| Carver, JR | 1 |
| Rodeheffer, RJ | 1 |
| Ivanhoe, RJ | 1 |
| DiBianco, R | 2 |
| Zeldis, SM | 1 |
| Hendrix, GH | 1 |
| Bommer, WJ | 1 |
| Elkayam, U | 1 |
| Kukin, ML | 1 |
| Kohn, IJ | 1 |
| Ribeiro, LG | 1 |
| Anderson, JL | 1 |
| Arnold, JM | 1 |
| Ribeiro, JP | 1 |
| Colucci, WS | 2 |
| DeFelice, A | 1 |
| Fein, S | 1 |
| Daudiss, K | 1 |
| Frering, R | 1 |
| Horan, P | 1 |
| Shabetai, R | 1 |
| Kostuk, W | 1 |
| Moran, J | 1 |
| Schlant, RC | 1 |
| Wright, R | 1 |
| Weber, KT | 2 |
| Janicki, JS | 2 |
| Maskin, CS | 1 |
| LeJemtel, TH | 1 |
| Gumbardo, D | 1 |
| Chadwick, B | 1 |
| Rutman, HI | 1 |
| Sonnenblick, EH | 1 |
| Likoff, MJ | 1 |
| Andrews, V | 1 |
| Wilson, H | 1 |
| Rocci, ML | 1 |
| Cody, RJ | 2 |
| Müller, FB | 1 |
| Kubo, SH | 2 |
| Rutman, H | 2 |
| Leonard, D | 2 |
| Chatterjee, K | 1 |
| Simonton, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children[NCT02728128] | 53 participants (Actual) | Observational | 2016-08-31 | Completed | |||
| Heart Failure in Adult Patients With a History of Congenital Heart Disease.[NCT00208754] | 350 participants | Observational | 2004-05-31 | Terminated | |||
| 2- Inhaled Milrinone Prevents the Increase in Pulmonary Artery Pressure After CPB[NCT00819377] | Phase 2 | 124 participants (Anticipated) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for milrinone and Chronic Illness
| Article | Year |
|---|---|
[Combination therapy with PDE III inhibitor for heart failure].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Chronic | 2007 |
Phosphodiesterase inhibitors. Its role in heart failure therapy.
Topics: Calcium Channels; Chronic Disease; Cyclic AMP; Heart Failure; Humans; Milrinone; Myocardial Contract | 1990 |
Effects of new inotropic agents on exercise performance.
Topics: Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiac Output; Cardiotonic Agents; Chronic Dise | 1986 |
6 trials available for milrinone and Chronic Illness
| Article | Year |
|---|---|
OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalization.
Topics: Cardiotonic Agents; Chronic Disease; Heart Failure; Humans; Infusions, Intravenous; Milrinone; Patie | 2003 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Chronic Disease; Drug Evaluation; Fe | 1991 |
A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.
Topics: Administration, Oral; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Digoxin; Double | 1989 |
Milrinone for long-term therapy of severe heart failure: clinical experience with special reference to maximal exercise tolerance.
Topics: Adult; Aged; Captopril; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Drug Therapy, | 1986 |
Milrinone in the treatment of chronic cardiac failure: a controlled trial.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Cardiomyopathy, Dilated; Chronic Disease; Clinical | 1985 |
11 other studies available for milrinone and Chronic Illness
| Article | Year |
|---|---|
Dose-Response Head-to-Head Comparison of Inodilators Dobutamine, Milrinone, and Levosimendan in Chronic Experimental Pulmonary Hypertension.
Topics: Animals; Calcium; Chronic Disease; Dobutamine; Dose-Response Relationship, Drug; Hemodynamics; Hydra | 2017 |
Milrinone in advanced heart failure: dose and therapeutic monitor outside intensive care unit.
Topics: Adult; Cardiac Catheterization; Cardiotonic Agents; Chromatography, High Pressure Liquid; Chronic Di | 2014 |
Milrinone improves pulmonary hemodynamics and right ventricular function in chronic pulmonary hypertension.
Topics: Animals; Cardiotonic Agents; Chronic Disease; Dogs; Fourier Analysis; Hypertension, Pulmonary; Milri | 1997 |
Pharmacological strategies for improving diastolic dysfunction in the setting of chronic pulmonary hypertension.
Topics: Administration, Inhalation; Animals; Cardiotonic Agents; Chronic Disease; Diastole; Dogs; Heart Vent | 1998 |
Positive inotropic drug infusions for patients with heart failure: current controversies and best practice.
Topics: Cardiotonic Agents; Chronic Disease; Dobutamine; Dopamine; Female; Heart Failure; Hemodynamics; Home | 2002 |
Oral milrinone in severe chronic heart failure.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Chronic Disease; Cricetinae; Heart Failure; Human | 1992 |
Muscle blood flow during forearm exercise in patients with severe heart failure.
Topics: Adult; Aged; Cardiac Output, Low; Chronic Disease; Exercise; Female; Forearm; Hemodynamics; Humans; | 1990 |
Beneficial hemodynamic effects of milrinone in conscious rabbits with chronic aortic regurgitation.
Topics: Animals; Aortic Valve Insufficiency; Cardiotonic Agents; Chronic Disease; Echocardiography; Female; | 1989 |
Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? III. Antagonist's viewpoint.
Topics: Adrenergic beta-Agonists; Animals; Cardiotonic Agents; Chronic Disease; Death, Sudden; Dobutamine; H | 1988 |
Identification of the direct vasodilator effect of milrinone with an isolated limb preparation in patients with chronic congestive heart failure.
Topics: Adult; Aged; Cardiotonic Agents; Chronic Disease; Female; Forearm; Heart Failure; Hemodynamics; Huma | 1986 |
Acute dose range study of milrinone in congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Cardiotonic Agents; Chronic Disease; Dose-Response Relationship, | 1985 |